265 related articles for article (PubMed ID: 20345767)
1. In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing gamma-secretase inhibitors.
Yang T; Arslanova D; Xu X; Li YM; Xia W
J Neurochem; 2010 Jun; 113(5):1200-9. PubMed ID: 20345767
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors.
Arslanova D; Yang T; Xu X; Wong ST; Augelli-Szafran CE; Xia W
BMC Biotechnol; 2010 Mar; 10():24. PubMed ID: 20307292
[TBL] [Abstract][Full Text] [Related]
3. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
[TBL] [Abstract][Full Text] [Related]
4. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
5. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish.
Geling A; Steiner H; Willem M; Bally-Cuif L; Haass C
EMBO Rep; 2002 Jul; 3(7):688-94. PubMed ID: 12101103
[TBL] [Abstract][Full Text] [Related]
6. Role of γ-Secretase Inhibitors for the Treatment of Diverse Disease Conditions through Inhibition of Notch Signaling Pathway.
Mondal A; Bose S; Banerjee S; Pal D
Curr Drug Targets; 2021; 22(15):1799-1807. PubMed ID: 33992061
[TBL] [Abstract][Full Text] [Related]
7. γ-Secretase inhibitors and modulators for Alzheimer's disease.
Wolfe MS
J Neurochem; 2012 Jan; 120 Suppl 1(Suppl 1):89-98. PubMed ID: 22122056
[TBL] [Abstract][Full Text] [Related]
8. Proton myo-inositol cotransporter is a novel γ-secretase associated protein that regulates Aβ production without affecting Notch cleavage.
Teranishi Y; Inoue M; Yamamoto NG; Kihara T; Wiehager B; Ishikawa T; Winblad B; Schedin-Weiss S; Frykman S; Tjernberg LO
FEBS J; 2015 Sep; 282(17):3438-51. PubMed ID: 26094765
[TBL] [Abstract][Full Text] [Related]
9. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
Beher D; Graham SL
Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
[TBL] [Abstract][Full Text] [Related]
10. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila.
Micchelli CA; Esler WP; Kimberly WT; Jack C; Berezovska O; Kornilova A; Hyman BT; Perrimon N; Wolfe MS
FASEB J; 2003 Jan; 17(1):79-81. PubMed ID: 12424225
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of γ-Secretase Leads to an Increase in Presenilin-1.
Sogorb-Esteve A; García-Ayllón MS; Llansola M; Felipo V; Blennow K; Sáez-Valero J
Mol Neurobiol; 2018 Jun; 55(6):5047-5058. PubMed ID: 28815510
[TBL] [Abstract][Full Text] [Related]
12. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
[TBL] [Abstract][Full Text] [Related]
13. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
14. gamma-Secretase as a therapeutic target in Alzheimer's disease.
Guardia-Laguarta C; Pera M; Lleó A
Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
[TBL] [Abstract][Full Text] [Related]
16. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
[TBL] [Abstract][Full Text] [Related]
17. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway.
Bittner T; Fuhrmann M; Burgold S; Jung CK; Volbracht C; Steiner H; Mitteregger G; Kretzschmar HA; Haass C; Herms J
J Neurosci; 2009 Aug; 29(33):10405-9. PubMed ID: 19692615
[TBL] [Abstract][Full Text] [Related]
18. JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo.
Petit A; Pasini A; Alves Da Costa C; Ayral E; Hernandez JF; Dumanchin-Njock C; Phiel CJ; Marambaud P; Wilk S; Farzan M; Fulcrand P; Martinez J; Andrau D; Checler F
J Neurosci Res; 2003 Nov; 74(3):370-7. PubMed ID: 14598313
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
20. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
